Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches
Cancers · 18.03.2026 · 18 (6) · 980
DOI: 10.3390/cancers18060980 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.03.2026. Verfasst von Yangzhi Ou und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Guangxi Science and Technology Major Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Myeloid-derived suppressor cells (MDSCs) drive immunosuppression in the hepatocellular carcinoma (HCC) tumor microenvironment (TME), contributing to immune checkpoint blockade (ICB) resistance. This review explores underlying mechanisms and therapeutic strategies.
Methods
We synthesize the recent literature on MDSC biology in HCC, focusing on signaling pathways, metabolic/epigenetic reprogramming, and novel interventions, including AI-driven analyses.
Results
Key mechanisms include JAK–STAT3 activation for MDSC expansion, CXCL12-CXCR4 for recruitment, enhanced glycolysis/lipid metabolism for suppressive function, and epigenetic changes sustaining immunosuppression. Therapeutic approaches encompass inhibitors, differentiation promoters, metabolic modulators, transcriptional reprogramming, microbiome modulation, and combinations with ICB/locoregional therapies or standard chemoimmunotherapy, yielding improved outcomes in trials.
Conclusions
Targeting MDSC redundancies via multi-modal strategies offers a roadmap for overcoming resistance, with AI enhancing biomarker-guided precision immunotherapy in HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Targeting Oncology, Guangxi Medical University, Nanning 530021, China.
- National Center for International Research of Bio-Targeting Theranostics, Guangxi Medical University, Nanning 530021, China.
- Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning 530021, China.
- Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning 530021, China.
- Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning 530021, China.
- Targeting Theranostics Research Center of Guangxi Higher Education, Guangxi Medical University, Nanning 530021, China.
Förderung
- the National Natural Science Foundation of China
- the Guangxi Science and Technology Major Program
- National Natural Science Foundation of China
- Guangxi Science and Technology Major Program
- National High-Level Talent Support Program
- National Ten Thousand Talent Program
Zitieren
APA
Ou, Y., Wei, H., Peng, C., Li, J., Wei, K., Zhan, C., & Zhang, Z. (2026). Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches. Cancers, 18(6), 980. https://doi.org/10.3390/cancers18060980
Vancouver
Ou Y, Wei H, Peng C, Li J, Wei K, Zhan C, et al. Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches. Cancers. 2026;18(6):980. doi:10.3390/cancers18060980
BibTeX
@article{Ou2026,
author = {Ou, Yangzhi and Wei, Huaxiu and Peng, Chunxiu and Li, Jin and Wei, Ke and Zhan, Chenjie and Zhang, Zhiyong},
title = {Overcoming MDSC-Mediated Immunosuppression in Hepatocellular Carcinoma: From Mechanisms to Novel Immunotherapeutic Approaches},
journal = {Cancers},
year = {2026},
volume = {18},
number = {6},
pages = {980},
doi = {10.3390/cancers18060980}
}
EUVIMED